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Abstract
The effects of an analgesic treatment (lidocaine patches) on brain activity in chronic low back pain
(CBP) and in knee osteoarthritis (OA) were investigated using serial fMRI (contrasting fMRI
between before and after two weeks of treatment). Prior to treatment brain activity was distinct
between the two groups: CBP spontaneous pain was associated mainly with activity in medial
prefrontal cortex, while OA painful mechanical knee stimulation was associated with bilateral
activity in the thalamus, secondary somatosensory, insular, and cingulate cortices, and unilateral
activity in the putamen and amygdala. After 5% lidocaine patches were applied to the painful body
part for two weeks, CBP patients exhibited a significant decrease in clinical pain measures, while in
OA clinical questionnaire based outcomes showed no treatment effect but stimulus evoked pain
showed a borderline decrease. The lidocaine treatment resulted in significantly decreased brain
activity in both patient groups with distinct brain regions responding in each group, and sub-regions
within these areas were correlated with pain ratings specifically for each group (medial prefrontal
cortex in CBP and thalamus in OA). We conclude that the two chronic pain conditions involve
distinct brain regions, with OA pain engaging many brain regions commonly observed in acute pain.
Moreover, lidocaine patch treatment modulates distinct brain circuitry in each condition, yet in OA
we observe divergent results with fMRI and with questionnaire based instruments.
Background
Mechanisms underlying CBP and OA pain states are
undoubtedly different, and for the most part remain
uncharacterized. Peripherally, CBP is mostly a conse-
quence of musculoskeletal and neural damage [1], though
accumulating evidence also implicates central, particu-
larly supraspinal, processes in the signs and symptoms of
the condition [2-5]. OA pain, in contrast, has generally
been characterized as a chronic inflammatory response
[6], although other mechanisms, such as the upregulation
of Na channels [7] and increased local production of NO
(contributing to cartilage degradation and inflammation)
[8] have recently been identified. While there is little evi-
dence specifically concerning central processes in OA
pain, animal model studies [9,10] and human sensory
testing [11] indicate reduced pain thresholds at sites
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removed from the OA joint that resolve in humans after
joint replacement, implying that central sensitization [12]
may contribute to OA pain.
A recent study characterizing pain properties on a ques-
tionnaire shows that OA and CBP (without radiculopa-
thy) patients have similar subjective symptoms but differ
from patients with signs of neuropathic pain [13]. Moreo-
ver, recent open-labeled clinical trials show the efficacy of
5% lidocaine patch (Lidoderm) therapy on pain in both
CBP [14-16] and OA patients [17,18]. Lidocaine patch
treatment is approved therapy for post-herpetic neuralgia
(PHN) [19], and in two recent studies we described its
effects on brain activity in PHN patients regarding sponta-
neous pain [20] and tactile allodynia pain [21], showing
that spontaneous pain and related brain activity decrease
with treatment, while stimulus evoked tactile allodynia
and its related activity remain unaffected. Here we study
brain activity for spontaneous pain in CBP and knee joint
stimulation evoked pain in OA patients, comparing the
effects of lidocaine therapy within and between the condi-
tions. As CBP is manifested primarily as a continuous,
spontaneous pain condition [22] and OA as more of an
evoked pain state exacerbated by knee bending during sit-
ting, walking or climbing steps [23,24], our primary
hypothesis is that brain activity should be distinct
between the two pain conditions. Moreover, given that in
PHN patients we have shown that lidocaine therapy is
more efficacious on spontaneous pain in contrast to
touch-evoked pain [21,25], here we hypothesize that lido-
caine therapy should be more effective on spontaneous
pain in CBP patients.
Methods
Subjects and screening procedures
Eleven CBP and eight OA patients were recruited. Com-
plete fMRI data were collected only in eight CBP and five
OA patients and only these data were analyzed. CBP
patients were included if they fulfilled the IASP criteria for
CBP [26], and were diagnosed in accordance with recent
guidelines [27]. OA patients were included if they fulfilled
the criteria of the American College of Rheumatology for
the classification of OA [28]. All the patients reported
chronic pain for a duration longer than 3 months with a
pain magnitude of at least 30/100 on a visual analog scale
(VAS). Clinical properties are summarized in Table 1 and
Table 2 respectively. Participants signed written informed
consent to the experimental procedure, which was
approved by the Northwestern University Institutional
Review Board.
Pain characteristics were determined using validated ques-
tionnaires. At every visit, CBP and OA patients filled the
short form of McGill Pain Questionnaire (sf-MPQ) [29].
Additionally, CBP patients filled the Neuropathic Pain
Scale (NPS) [30], and OA patients filled the Western
Ontario and McMaster Osteoarthritis Index (WOMAC)
[31].
Experimental design and pain ratings
During each session patients were scanned under two dif-
ferent conditions: 1) pain rating (up to three scans per ses-
sion) where patients were asked to report the intensity of
their pain using a finger-span logging device. Prior to
scanning, patients learned how to use the device to con-
tinuously report changes in their pain intensity while
observing their rating projected on a computer screen as a
moving bar (size of the bar is a scale from 0 to 100; 0 = no
pain; 100 = worst imaginable pain); 2) one visual control
scan where patients used the finger-span device to rate the
length of a bar moving at a rate approximating the varia-
bility of their pain (for more details see, [32,33]. The vis-
ual task served as a motor-attention-cognitive control for
non-specific brain activations due to finger motion and
attention. During the pain rating task CBP patients
reported the fluctuations of their spontaneous pain inten-
sity in the absence of an overt experimental stimulus. On
the other hand, OA patients rated pain in response to
pressure applied to the most sensitive part of their bad
knee. Pressure was delivered using a custom-made fMRI
compatible device equipped with a feedback signal
regarding applied pressure. The finger device and pressure
Table 1: Clinical characteristics for chronic back pain patients
CBP Patients Age (years) Sex Pain duration (years) VAS Below knee radiation Herniated
disc
Medications
1 58 M 5 70 Yes Yes Ibuprofen/acetaminophen
2 29 F 3 60 Yes No MRI none
3 32 F 7 80 No Yes Valium, skelaxin, naproxen, 
ibuprofen
4 43 F 12 50 No Yes Acetaminophen/naproxen
5 59 M 30 65 Yes No Ibuprofen
6 47 M 10 55 Yes Yes Ibuprofen/Flexeril
76 8 M46 0 N o N o I b u p r o f e n
Herniated disc, based on spinal MRI. M = male, F = female. VAS score is for spontaneous pain.Molecular Pain 2008, 4:47 http://www.molecularpain.com/content/4/1/47
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signal were synchronized and time locked with the fMRI
image acquisition sequence. During each scan, OA
patients were presented with up to six stimulation epi-
sodes with variable intensities (range: 2–13 s.u., mean ±
standard deviation : 5.5 ± 4.8 s.u., s.u. = standardized
units; absolute pressure values were not used due to their
strong dependence on the physical location of the stimu-
lus on the knee), durations (range: 20 – 45 seconds,
mean: 32.2 ± 15 seconds) and inter-stimulus intervals
(range: 30 – 60 seconds, mean 42.8 ± 16 seconds). Exam-
ples of one CBP and one OA pain-rating task are shown in
Figure 1. The applied pressure and the patient's rating of
related pain were collected during scanning and used to
relate brain activity to perceived pain.
Functional magnetic resonance data acquisition
Functional MRI data was acquired with a 3T Siemens Trio
whole-body scanner with echo-planar imaging (EPI)
capability using the standard radio-frequency head coil.
Multi-slice T2*-weighted echo-planar images were
obtained with the following parameters: repetition time
TR = 2.5 s, echo time TE = 30 ms, flip angle = 90°, slice
thickness = 3 mm, and in-plane resolution = 3.475 ×
3.475 mm2. The 36 slices covered the whole brain from
cerebellum to vertex. Two hundred and forty volumes
were acquired per scan. A T1-weighted anatomical MRI
image was also acquired for each subject using the follow-
ing parameters: TR = 2.1 s, TE = 4.38 ms, flip angle = 8°,
FOV = 220 mm, slice thickness = 1 mm, in-plane resolu-
tion = 0.86 × 0.86 mm2, and number of sagittal slices =
160.
fMRI data analysis
Image analysis to reveal significant brain activity based on
changes in BOLD signal was performed on each subject's
data using FMRIB Expert Analysis Tool (FEAT, [34], http:/
/www.fmrib.ox.ac.uk/fsl). The preprocessing of each sub-
ject's time-series of fMRI volumes encompassed: slice time
correction; motion correction using MCFLIRT; spatial
smoothing using a Gaussian kernel of full-width-half-
maximum 5 mm; nonlinear high-pass temporal filtering
(Gaussian-weighted least-squares straight line fitting, fil-
ter cutoff of 100 seconds) and subtraction of the mean of
each voxel time-course from that time-course (i.e. inten-
sity normalization). The fMRI signal was then linearly
modeled on a voxel by voxel basis using FMRIB's
Improved Linear Model (FILM) with local autocorrelation
correction [35,36].
Each condition described above (rating of spontaneous
pain in CBP, rating of stimulus pain in OA, and rating of
visual stimuli in both populations) was considered to
generate a hemodynamic response described by the con-
volution of the corresponding vector with a canonical
hemodynamic response function (gamma function: lag =
6 seconds, standard deviation = 3 seconds). Head motion
vector (derived from motion correction) was used at this
level as a covariate of no interest to further remove any
residual variance due to head motion. The significance of
the model fit to each voxel time-series was calculated,
yielding statistical parametric maps for the pain and visual
rating conditions in each subject.
Average group activity pain maps for OA and CBP for in
session 1 and session 2 were generated by first subtracting
the visual task related activity from the pain related activ-
ity map for each subject using FEAT in a higher level fixed
effects analysis following the co-registration of individual
scans to standard space (152 subject average MNI space,
http://www.bic.mni.mcgill.ca/cgi/). This results in a con-
trast of parametric estimate (COPE) map of statistically
significant pain minus visual activity for each patient.
Group average pain minus visual activity maps were then
generated by averaging COPE maps for CBP (n = 7) and
OA (n = 5) in a third higher level fixed effects analysis. The
resultant group average pain minus visual maps were
thresholded at z-scores > 2.3, and a cluster probability
threshold of p = 0.01 was applied to compute the signifi-
cance of each cluster, thereby correcting for multiple com-
parisons [37]. Group average pain minus visual brain
activity for CBP and OA are shown in Figure 2.
Brain regions exhibiting a significant decrease in activity
in response to lidoderm treatment in CBP and OA were
identified using a paired t-test (fixed effects analysis, z-
score > 2.3, cluster threshold p = 0.01) between the
higher-level (pain – visual) COPEs statistical images of
session 1 and session 2. The resultant z-map for session 1
Table 2: Clinical characteristics for osteoarthritis patients
OA Patients Age (years) Sex Pain Duration (years) VAS Knee pain History of trauma Medications
1 54 F 3 50 L>R No Celecoxib
2 61 M 30 40 R Yes Aspirin
3 61 M 3 60 L>R No Acetaminophen
4 54 M 21 80 R>L Yes Relafen/Aspirin
5 63 M 2.5 70 L>R No Ibuprofen
L = left, R = right. M = male, F = female. VAS score is for pain in the absence of stimulation.Molecular Pain 2008, 4:47 http://www.molecularpain.com/content/4/1/47
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Pain ratings and treatment effects on pain Figure 1
Pain ratings and treatment effects on pain. A. An example of pain ratings in CBP and OA. CBP patients rated spontane-
ous fluctuations in their pain intensity in the absence of an overt experimental stimulus (top). OA patients rated the fluctua-
tions in their pain intensity in response to a pressure stimulus (gray) applied on the affected knee. B. CBP patients exhibited a 
significant decrease in pain after 2 weeks of topical Lidocaine treatment as measured by VAS (p < 0.01) and average pain during 
the scan (p < 0.05) (right bar graphs). OA patients did not show any decrease in pain after treatment as measured by VAS (p = 
0.5), and a borderline decrease in pain in response to pressure stimulation (computed as average pain during scan divided by 
average pressure in standardized units) (p = 0.06) (left bar graphs). Error bars are standard deviations.Molecular Pain 2008, 4:47 http://www.molecularpain.com/content/4/1/47
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Brain activity maps for CBP and OA Figure 2
Brain activity maps for CBP and OA. CBP and OA group average brain activity maps (fixed effects analysis) for session1 
(prior to treatment), session 2 (2 weeks after application of Lidoderm) and contrast between before and after treatment (scan 
1 > scan 2). Each scan map is a subtraction between the pain rating task and the control visual rating task.Molecular Pain 2008, 4:47 http://www.molecularpain.com/content/4/1/47
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minus session 2 for each patient population was then
masked with its respective group average activity of the
pain minus visual of session 1 to eliminate false positive
results. These maps thus depict the brain areas showing
pain-specific activity that significantly decreased with
treatment.
To determine those brain regions encoding pain intensity,
we performed a whole brain covariate analysis using FSL
(fixed effects analysis, z-score > 2.3, cluster threshold p =
0.01) across CBP and OA patients. For CBP, the first level
pain activity maps were pooled from session 1 and 2 (n =
42) and regressed with the average spontaneous pain dur-
ing the scan. Similarly, the first level OA pain activity
maps were pooled from sessions 1 and 2 (n = 37) and
regressed with average pain divided by applied pressure,
thereby normalizing perception to unit intensity of
applied stimulus. We used standardized stimulus units
rather than absolute values of pressure to account for the
variability of pressure intensities necessary to induce pain
across the knee. The z-maps for the covariate analysis for
CBP and OA were then masked with their respective group
average activity for pain minus visual contrast, to restrict
the analysis to pain specific brain regions. To show the
relationship of brain activity and pain intensity in more
detail, we also performed a region of interest analysis
(ROI). For each scan, we extracted the z-values of a 1 cc
ROI centered on the peaks obtained in the covariate maps
and examined their relationship to perceived pain (Figure
3).
To delineate the brain regions encoding pain intensity
that were also modulated by treatment, we performed a
whole brain voxel-wise conjunction analysis between the
thresholded z-map for treatment and the pain intensity
covariate maps for CBP and OA. For each patient group
we then identified the ROIs from the conjunction map
and extracted their z-values from a 1 cc volume and used
them to perform an unpaired t-test between session 1 and
session 2.
Covariate analysis of brain activity with pain intensity in CBP and OA Figure 3
Covariate analysis of brain activity with pain intensity in CBP and OA. A. Covariate map shows brain regions that 
encoded pain intensity in CBP. It identifies the rostral ACC and mPFC. Scatter plots show the relationship between pain inten-
sity and z-values (averaged within 3 × 3 cluster around the peak) in mPFC and right thalamus (identified from OA covariate 
analysis) in CBP. B. Covariate map for OA. It shows many brain regions, none overlap with the region seen in CBP. Scatter 
plots are in OA for the same regions shown in A.Molecular Pain 2008, 4:47 http://www.molecularpain.com/content/4/1/47
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Surface-based mapping
Surface-based mapping (figures 2 and 3) was constructed
using the Population-Average, Landmark- and Surface-
based (PALS) average fiducial surface from 12 individual
subjects as the atlas target [38].
Results
Behavior
CBP patients showed a robust decrease in pain intensity as
well as other clinical pain parameters in response to a two-
week topical Lidocaine treatment applied to the back.
Pain intensity was assessed from VAS scores obtained in
sf-MPQ, and by averaging the spontaneous pain reported
by the subject during the scan. Both of these measure-
ments exhibited significant reduction after treatment (Fig-
ure 1B, Table 3). In addition, CBP patients showed a
significant decrease in the surface score (p < 0.05) and
borderline significant decreases for the deep, unpleasant-
ness, and overall neuropathic pain score (Table 3).
In contrast to CBP, OA patients did not show improve-
ment after Lidocaine treatment in their knee pain as meas-
ured by VAS in sf-MPQ, or by intensity of mean pain
ratings for knee stimulation, and other OA related pain
characteristics on either sf-MPQ or on WOMAC. They did
exhibit however a borderline decrease in ratings of knee
pain (p = 0.06) after normalization with applied pressure
(Figure 1B, Table 3).
Brain activity in CBP and OA
Before treatment (session 1), spontaneous pain in CBP
gave rise to increased brain activity mainly in the frontal
cortex, including the medial prefrontal cortex (mPFC), the
rostral anterior cingulate cortex (rACC), bilateral superior
frontal gyrus (SFG), and the nucleus accumbens (NAc).
Increased activity was also observed in the inferior tempo-
ral gyrus (ITG), and the left posterior parietal cortex (PP).
Therefore, CBP is represented mainly in emotion/reward
(mPFC and NAc) mediating areas as reported previously
[39]. After treatment (session 2), only a small cluster in
the left MT area showed significant increased activity for
spontaneous pain (Figure 2, Table 4).
Evoked knee OA pressure-pain, on the other hand,
showed more extensive activity pattern, with similarities
to activity for acute pain in normal subjects [40]. Before
treatment (session 1), painful knee stimulation evoked
activity in: bilateral thalamus, secondary somatosensory
cortex (SII), insula, supplementary motor area (SMA),
anterior cingulate (ACC) and medial frontal gyrus; and
unilaterally in right putamen, and left amygdala. After two
weeks of treatment (session 2), the brain activity map was
similar with some exceptions. No significant activity was
observed in the left amygdala, right putamen, and left
anterior insula. Additionally a new, large activation was
observed in right ventrolateral orbitofrontal (VLOFC), as
well as more activations in mid temporal and visual corti-
ces (Figure 2, Table 4).
Treatment effect on brain activity
As we noted earlier, treatment of CBP with lidocaine led
to a significant decrease in pain intensity rating. This was
accompanied by a significant decrease in brain activity in
mPFC, rACC, SFG, and PP when maps from session 1 and
2 were statistically contrasted. In OA, lidocaine treatment
only showed a borderline decrease in pain per applied
pressure, but the statistical contrast between session 1 and
2 indicated significantly decreased brain activity in left
MFG, left anterior insula, and bilateral thalamus (Figure
2, Table 4).
Covariate analysis
Brain areas encoding pain intensity in CBP and OA were
identified using a covariate analysis. In CBP the covariate
was mean spontaneous pain during the scan, and in OA
the covariate was the mean pain during the scan divided
by the normalized applied pressure. The mPFC and parts
of the rACC at the level of the genu encoded pain intensity
Table 3: Pain parameters and clinical data for CBP and OA patients
CBP OA
Session1 Session2 p-value Session 1 Session 2 p-value
Pain Int. 49.5 ± 19 27.2 ± 18.1 0.034 Pain Int. 39.6 ± 14.3 37.2 ± 12.6 0.513
VAS 62.3 ± 9.9 34.3 ± 19.6 0.008 VAS 55.5 ± 12.3 52.5 ± 11.9 0.501
Affective 3.4 ± 4.5 2.3 ± 4.4 0.331 Affective 0.5 ± 1.0 1.5 ± 1.0 0.308
Sensory 11.1 ± 9.2 8.3 ± 10.1 0.482 Sensory 9.3 ± 1.7 6.3 ± 3.9 0.334
NPS (N) 17.8 ± 13.7 9.9 ± 8.4 0.055 Pain (W) 10.0 ± 1.6 9 ± 2.4 0.252
Unpleas. (N) 5.2 ± 1.3 3.4 ± 2.1 0.094 Stiffness (W) 5.0 ± 1.4 5.0 ± 1.4 1.000
Deep (N) 6.6 ± 1.7 3.5 ± 2.6 0.082 Activity (W) 35.2 ± 4.9 31.5 ± 9.1 0.243
Surface (N) 4.2 ± 1.9 1.9 ± 2.3 0.025 Pain Int./Pr 29.3 ± 10.4 23.1 ± 8.3 0.0622
Session 1 = prior to use of Lidoderm therapy; Session 2 = after 2 weeks of Lidoderm therapy. Pain Int. = mean pain rating during the scan; Pain Int./Pr 
= mean pain rating during the scan divided by normalized applied pressure.VAS = visual analog scale; Unpleas = unpleasantness; VAS, Affective and 
Sensory are from McGill short form. N = Neuropathic Pain Scale; W = WOMAC. All parameters are expressed as μ ± S.D. p values were computed 
using a paired t-test.Molecular Pain 2008, 4:47 http://www.molecularpain.com/content/4/1/47
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in CBP (figure 3A). In contrast, the mid ACC, right insula,
bilateral thalamus, right S2 and right MFG encoded pain/
pressure in OA (figure 3B). Thus, pain intensity represen-
tation in CBP and OA (normalized with pressure in OA)
pain map to different brain regions.
To show the relationship of brain activity and pain inten-
sity in more detail, we performed a region of interest anal-
ysis. For each scan, we extracted the z-values of a 1 cc ROI
centered on the peaks obtained by the covariate maps. The
ROIs used include mPFC (2,42,2), left thalamus (12,-
20,4), right insula (40,8,-4), right S2 (46,-18,32), mid
ACC (-4,24,28) and right middle frontal gyrus (MFG) (38,
38, 36). The mPFC showed a significant correlation with
pain intensity for CBP (p < 0.01) but not for OA, while the
left thalamus was positively correlated with pain intensity
for OA (p < 0.01) but not CBP (figure 3). The insula, S2
mid-ACC, right MFG also showed positive correlations
with pain intensity for OA, with p values of 0.035, 0.042,
0.041, and 0.039 respectively, but not for CBP.
Change in brain regional activity with treatment
The covariate analysis indicates the brain regions where
brain activity reflects pain intensity, while the contrast
Table 4: Brain regions activated for CBP and OA
Brain region Session 1 Session 2 Session 1 > Session 2
Coordinates
x, y, z
Z-score Coordinates
x, y, z
Z-score Coordinates
x, y, z
Z-score
CBP (Pain-Visual)
mPFC (32/10) 2, 48, 2 10.5 6, 52, -8 5.85
R ACC (32) -2, 38, 20 7.72 -2,38,20 4.31
L SFG (8) -16, 32, 46 9.76 -16,30,44 6.91
R SFG (8) 16,22,52 7.66
NAc 6, 12, -10 8.46
L ITG (20) -56, -8, -32 6.36
L PP (7) -48, -72, 38 8.18 -46, -74,44 6.12
L MT -64, -44, -10 4.12
OA (Pain-Visual)
R VLOFC (10/11) 44, 42, -14 6.27
L MFG (9/46) -36, 42, 6 4.88 -38, 52, 12 4.19
R MFG (9/46) -40, 36, 32 4.78
ACC (32) -4, 38,22 4.96
L Ant Insula/IFG -36, 28, -8 4.07 -36, 28, -8 4.39
ACC (24) -8, 22, 28 4.34 6, 30, 26 4.57 -4, 24, 28 2.63
R MFG (8/9) 50, 14, 48 3.7 40, 18, 52 4.65
L Putamen -22, 14, -2 4.59
SMA (6/8) 2, 8, 62 4.25 10,16,62 4.35
L Insula (48) -36, 6,4 3.72 -40, 8, -6 5.12
R Insula (48) 42, 6, -4 5.75 38, 18, -8 3.09
R Putamen 26, 6, -2 3.23 -18, 14, -2 6.22
L Amygdala -20, -6, -18 3.17
R Thalamus 14, -18, 2 5.6 16, -18, 4 4.39 12, -18, 0 4.00
L Thalamus -8, -22, 0 6.14 -16, -16,4 4.42 -6, -22, 0 3.62
L SI/MI (3/4) -38, -24,56 6.12
L S2 -54, -26, 24 4.87 -58, -28, 26 5.01
R S2 52, -28, 24 2.87 54, -24, 26 4.67
Pre-cuneus (7) 0, -52, 68 5.88
L PP (7) -28, -52, 54 5.46
L MT -56, -64,4 5.36
R PP 22, -76,48 5.5
L Visual cortex -12, -80, -12 6.1
L = left; R = right; mPFC = medial prefrontal cortex; DLPFC = dorsolateral prefrontal cortex; S2 = secondary somatosensory cortex; M1 = primary 
motor cortex; ACC = anterior cingulate; SMA = supplementary motor area; LP = lateral parietal cortex; PP = posterior parietal cortex; IFG = 
inferior frontal gyrus; NAc = nucleus accumbuns; ITG = inferior temporal gyrus; SFG = superior frontal gyrus; MT = middle temporal cortex; 
VLOFC = ventrolateral orbitofrontal cortex. Numbers in parenthesis = Brodmann areas. Minus denotes left, posterior and ventral to the anterior 
commissure for x, y, and z mm, respectively.Molecular Pain 2008, 4:47 http://www.molecularpain.com/content/4/1/47
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between the pain rating and visual rating tasks between
session 1 and 2 shows brain regions specifically involved
in pain that decrease with treatment. To identify brain
regions that both code pain and decrease with treatment
we performed a conjunction analysis between the covari-
ate and contrast analyses, for both OA and CBP patients.
In CBP this resulted in a single cluster in the mPFC (-2, 48,
2) with activity z-value of 3.11 ± 1.78 in session 1 and
0.98 ± 0.98 in session 2, showing a large treatment effect
(t = 8.386; p < 0.001). In OA only bilateral thalamus sur-
vived: with the larger change seen in left thalamus (-12, -
20, 2; with session 1 z-value of 3.21 ± 0.93; session 2 z-
value of 1.12 ± 0.96; and treatment effect t = 8.89; p <
0.001); and a similar but smaller change seen in the right
thalamus (16, -18, 4; session1 z-value 2.98 ± 0.92; session
2 z-value 0.97 ± 0.88; and treatment effect t = 7.15; p <
0.01).
Discussion
A wealth of data exists regarding the clinical pain charac-
teristics of CBP and OA. To our knowledge, this is the first
study examining brain activity in both conditions, before
and after an analgesic treatment the efficacy of which
remains unproven in both conditions.
The results indicate that brain activity in CBP for sponta-
neous pain is different from brain activity for mechani-
cally evoked knee pain in OA. While CBP pain related
brain activity mapped mainly to the mPFC and adjacent
rACC, the evoked OA pain mapped to many areas com-
monly seen in acute pain in [41], in addition to regions
that seem more uniquely activated in the condition: the
MFG, and amygdala. Moreover, the pattern of pain inten-
sity encoding was distinct between evoked OA pain and
spontaneous CBP. While the former correlated to brain
activity in the thalamus, insula, mid-ACC, S2, and MFG,
the latter correlated to activity in mPFC/rACC. Further-
more, modulation of afferent input with lidocaine
patches gave rise to different patterns of change in behav-
ior and in brain activity depending on the condition. The
results corroborate our general hypothesis, that different
clinical chronic pain conditions have distinct brain activ-
ity patterns, which in part is a function of the type of pain
investigated.
Both patient groups studied use similar drugs for pain
relief, and have similar durations of chronicity and clini-
cal characteristics. As both groups also describe their pain
similarly on the NPS scale [42], and as recent studies show
efficacy of lidocaine patch treatment in pain relief in both
groups [14,15,18,43,44], we reasoned that comparing
brain activity and responses to this treatment between the
two groups was meaningful. Despite these similarities,
brain activity is distinct for knee stimulation pain in OA
from spontaneous pain in CBP.
We examined spontaneous pain in CBP, as this is the most
relevant clinical pain issue in CBP patients. On the other
hand, we resorted to studying knee-stimulation evoked
pain in OA because there was minimal fluctuation in
spontaneous pain when these subjects were at rest and the
knee not provoked. It therefore remains unclear whether
OA patients even have spontaneous pain or if the non-
stimulated pain reported by OA patients is a reflection of
the after effects of manipulations to the knee. A recent
study described brain activity in OA in the absence of
stimulation [45]. Thus, their results might reflect brain
regions involved in spontaneous pain in OA. The reported
activation pattern resembles activity for knee-stimulation
evoked pain described here, and also a large mPFC activa-
tion that matches the activity we see for spontaneous pain
in CBP. Kulkarni et al. mention that the pain was a reflec-
tion of the "ongoing knee pain experienced during
patients' accustomed physical activities", suggesting that
the reported activity may be due to previous provocation
of the painful joints. Still, it should be emphasized that
Kulkarni et al.'s results highlight the fact that OA pain
engages sensory regions of the cortex even in the absence
of a stimulus.
This study and our previous work [46,47] demonstrate
that spontaneous pain intensity encoding is comparable
between CBP patients and post-herpetic neuralgia (PHN)
patients. In both cases it is encoded, though with some
differences, in areas normally involved in hedonic experi-
ence and emotional learning, such as the mPFC/rACC and
orbitofrontal cortex [48-52], in reward and goal directed
behavior such as the striatum [53], and in fear behavior
such as the amygdala [54]. Furthermore, those are the pri-
mary areas modulated by lidocaine patch treatment in
both conditions. Thus both CBP and PHN spontaneous
pain appear to be primarily emotional states, with lido-
caine patch therapy decreasing this emotional pain. In
contrast, knee-stimulation evoked pain related brain
activity was mostly sensory and the activity in these sen-
sory pain representational areas specifically decreased
with lidocaine patch therapy.
Lidocaine patch acts through blockade of abnormally
functioning (sensitized) Nav1.7 and Nav1.8 Na+ chan-
nels in dermal nociceptors, thereby reducing ectopic dis-
charges [55,56]. Lidocaine has also been shown to
regulate T-cell activity and inhibit NO production [57,58].
It is thus likely that the decreased pain perception with
lidocaine patch therapy is due to its effect on sensitized
nociceptors, as well as to decreasing inflammatory proc-
esses within the deep tissue such as injured muscle, joint,
tendon, and constricted nerves that provide the afferent
input contributing to the pain of CBP and/or OA. The
extent to which lidocaine can penetrate these injured
structures in the deep tissue may be one explanation for itsMolecular Pain 2008, 4:47 http://www.molecularpain.com/content/4/1/47
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better effectiveness in CBP. We cannot, however, distin-
guish between multiple implications: distinct fiber types
being involved in each type of pain and yet both respond-
ing to lidocaine patch therapy; same afferents being mod-
ulated with the therapy but distinct spinocephalad
pathways signaling nociceptive inputs, and thus affecting
different cortical activity; or some combination of both.
The evoked OA pain in this study elicits activity patterns
and engages brain regions similar to those observed in
touch-evoked pain (allodynia) [21,59-61] and acute pain
[62]. However, intensity encoding of pain appears to be
represented by brain activity patterns specific to each clin-
ical condition. The insula and S2 in OA patients in the
present study, and in one case of psoriatic arthritis [63],
encode evoked pain intensity and these two regions were
responsive to a COX2-inhibitor that resulted in pain relief
in the psoriatic arthritis patient. However, in OA only
bilateral thalamus encoded pain intensity and responded
to lidocaine patch therapy. In comparison, in PHN
patients basal ganglia and medial temporal gyrus
responses were related to the ratings of tactile allodynia
[21].
The present results and earlier human brain imaging evi-
dence for differential involvement of distinct brain
regions in various clinical chronic pain conditions is con-
sistent and complimentary to accumulating evidence in
animal studies regarding the differential involvement of
cortical regions in various animal models of chronic pain.
Recent studies indicate that neuronal activity and receptor
properties of the amygdala are modified in persistent pain
conditions and these changes influence spinal cord neuro-
nal activity [64,65]. Changes in synaptic efficacy and sec-
ond messenger properties have also been observed in the
ACC in animal models of chronic pain, which were corre-
lated to the pain behavioral outcomes [66,67]. Thus these
studies potentially provide mechanistic explanations for
the different brain activity associated with OA and CBP
and their possible contribution to the resultant percep-
tions.
Technical issues
If we examine pain measures either by ratings or by ques-
tionnaire outcomes in the OA group, no treatment effects
are observed. The borderline treatment effect only shows
up when pain is divided with applied pressure, and this
parameter relates to statistically significant brain activity
changes. This is a normalization of perception per unit
stimulus, it is equivalent to earlier efforts of matching
pain perception by varying stimulus strength [68-70], and
might be a critical step in assessing pain treatment effects
on evoked pain, especially in clinical pain conditions.
In the present study, while the number of participants in
each group was small, the data was nonetheless reproduc-
ible enough to show significant changes in brain activity.
Due to the small number of subjects studied we have used
fixed effects statistics. Therefore, the obtained results can-
not be generalized to the population at large, neither for
CBP nor for OA.
Here we demonstrate that decreased brain activity with
treatment may be identified prior to the patients' report of
decreased pain on standard questionnaires commonly
used in clinical trials. Open labeled clinical trials indicate
decreases in OA pain, as measured by WOMAC or NPS
[18,71], even in small groups of patients. Therefore, it is
not clear why our OA patients did not have clinical signs
of decreased pain. The design of the present study was
based on the idea that painful mechanical stimuli applied
to the knee are relevant to knee OA, and that manipula-
tion of this pain should also have clinical relevance. We
are surprised that even though knee stimulation evoked
pain is modulated with the treatment, clinical question-
naires based outcomes are not. This is in contrast to the
CBP patients, at least suggesting that lidocaine therapy is
more efficacious in CBP. The discrepancy between ques-
tionnaire outcomes and stimulus-evoked pain implies
that in OA the clinical pain depends on factors more than
just the knee pressure-pain relationship. Therefore,
although we observe that lidocaine patch therapy modu-
lates the pressure-pain relationship and thalamic activity
reflects this modulation, we cannot conclude that this
effect is clinically significant. Alternatively, these results in
OA suggest that perhaps continued treatment for longer
durations and at higher doses may result in a clinically sig-
nificant outcome.
Conclusion
Overall, the diverse brain activation patterns in these two
groups of patients indicate that brain circuitry underlying
CBP spontaneous pain and OA joint stimulation evoked
pain are distinct. Moreover, distinct brain regions encode
and respond to lidocaine patch therapy. We also demon-
strate that, even in the absence of questionnaire based evi-
dence for pain relief; fMRI may provide clues suggesting
analgesic effects of a therapy. These studies lack a placebo
arm and were performed in a small number of patients.
The available data and the limited number of studies in
the topic, therefore, underscore the need for larger, pla-
cebo controlled fMRI trials for efficacy of lidocaine patch
therapy in both CBP and OA patients.
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